Community-Acquired Pneumonia - Adult

Quick Answer

Community-acquired pneumonia (CAP) is an acute lower respiratory tract infection acquired outside hospital, presenting with cough, fever, dyspnoea, and new infiltrates on chest X-ray. Streptococcus pneumoniae is the most common pathogen (30-50%). Emergency management involves oxygen therapy to maintain SpO₂ ≥92%, empirical antibiotics (amoxicillin + macrolide or β-lactam/β-lactamase inhibitor), and severity assessment using CURB-65 or PSI scores to guide disposition. Admit patients with CURB-65 ≥2, severe hypoxaemia, sepsis, or complications. Consider atypical pathogens (Mycoplasma, Legionella), viral causes (influenza, SARS-CoV-2), and aspiration in vulnerable populations.

---

ACEM Exam Focus

Fellowship Written:

• CURB-65 vs PSI severity scoring
• Empirical antibiotic selection (monotherapy vs dual therapy)
• Criteria for ICU admission
• Complications: pleural effusion, empyema, lung abscess
• Atypical pathogens and their investigation

Fellowship OSCE:

• Respiratory examination with interpretation of findings
• Breaking bad news (severe pneumonia with ICU admission)
• Prescribing antibiotics in penicillin allergy
• Communication with primary care for discharge planning
• Leading resuscitation of septic shock secondary to CAP

Common Viva Topics:

1. Outline the initial approach to a patient with suspected CAP in the ED
2. Compare CURB-65 and PSI scoring systems
3. When would you consider coverage for Pseudomonas or MRSA?
4. Describe the management of pneumonia in pregnancy

---

Key Points

1. Pathogen hierarchy: Streptococcus pneumoniae (30-50%), atypical organisms (15-30%), respiratory viruses (15-20%), Haemophilus influenzae (10-15%)
2. Severity scoring: CURB-65 ≥2 or PSI Class IV-V require hospital admission; CURB-65 ≥3 or PSI Class V may need ICU
3. Empirical antibiotics: Amoxicillin 1g TDS + azithromycin 500mg daily (or doxycycline 100mg BD) for moderate CAP; β-lactam/β-lactamase inhibitor + macrolide for severe
4. Investigations: CXR (posteroanterior and lateral), blood cultures if severe, sputum cultures if productive, pneumococcal and Legionella urinary antigens
5. Admission criteria: CURB-65 ≥2, severe hypoxaemia (SpO₂ below 90% on room air), sepsis, social factors, inability to tolerate oral intake
6. Discharge timing: Clinical stability criteria - temperature ≤37.8°C, heart rate ≤100, respiratory rate ≤24, SBP ≥90, SpO₂ ≥90% on room air, oral intake, normal mentation
7. Indigenous health: Aboriginal and Torres Strait Islander adults have 3-5x higher CAP incidence and mortality; Māori experience similar disparities

---

Epidemiology

Community-acquired pneumonia is a leading cause of infection-related morbidity and mortality worldwide.

Incidence

• General population: 2.5-11 per 1,000 adults per year (PMID: 29278410)
• Age greater than 65 years: 25-35 per 1,000 per year (PMID: 21048110)
• Seasonal variation: Winter peak (2-3x higher than summer) (PMID: 19501827)

Mortality

• Outpatient CAP: 1-5% mortality (PMID: 29278410)
• Hospitalized CAP: 5-15% in-hospital mortality (PMID: 33289525)
• ICU CAP: 20-50% mortality (PMID: 31573637)
• 30-day mortality: 10-15% for hospitalized patients (PMID: 21048110)

Risk Factors

• Age greater than 65 years (Odds ratio 3.0-5.0) (PMID: 21048110)
• Chronic lung disease (COPD, bronchiectasis) (PMID: 29278410)
• Smoking (Current smokers OR 2.5, ex-smokers OR 1.5) (PMID: 25520247)
• Immunosuppression (HIV, chemotherapy, corticosteroids, biologics) (PMID: 24797699)
• Chronic diseases: Diabetes (OR 1.3), heart failure (OR 1.5), chronic kidney disease (OR 2.0) (PMID: 21048110)
• Aspiration risk: Dysphagia, alcoholism, neurological disease (PMID: 29278410)
• Malnutrition (BMI below 18.5 kg/m²) (PMID: 25520247)

Australian/NZ Context

Aboriginal and Torres Strait Islander:

• 3-5x higher incidence of CAP compared to non-Indigenous Australians (PMID: 30760144)
• 2-3x higher mortality (PMID: 26040576)
• Higher rates of underlying lung disease (COPD, bronchiectasis) (PMID: 28691157)
• Greater prevalence of risk factors (smoking rates 40-50%, diabetes, chronic kidney disease) (PMID: 30335017)

Māori and Pacific Peoples (NZ):

• 2-3x higher hospitalization rates for CAP (NZ Ministry of Health data)
• Higher pneumococcal disease burden (PMID: 24933391)
• Socioeconomic barriers to early healthcare access

---

Pathophysiology

Microbial Invasion

Route of infection:

1. Aspiration of oropharyngeal flora (most common) - bacterial colonizers overcome host defences
2. Inhalation of aerosols (e.g., Legionella, Mycobacterium tuberculosis)
3. Haematogenous spread (rare - e.g., Staphylococcus aureus in septic emboli)

Host defence failure:

• Mucociliary clearance disruption (smoking, viral infection, chronic lung disease)
• Alveolar macrophage dysfunction (alcohol, smoking, corticosteroids)
• Impaired cough reflex (sedatives, stroke, neuromuscular disease)
• IgG or complement deficiency (immunosuppression)

Pathogen Spectrum

(PMID: 33289525, 29278410, 24797699)

Inflammatory Response

Alveolar phase:

1. Oedema (0-24h) - Bacterial invasion triggers vascular leak, protein-rich exudate fills alveoli
2. Red hepatization (24-48h) - Neutrophil infiltration, red blood cells in exudate
3. Grey hepatization (48-72h) - Fibrin deposition, neutrophil disintegration
4. Resolution (7-14 days) - Macrophage clearance, regeneration of epithelium

Systemic effects:

• Cytokine release (IL-1, IL-6, TNF-α) → fever, tachycardia, leukocytosis
• Hypoxaemia - V/Q mismatch, shunt, diffusion impairment, increased oxygen consumption
• Cardiovascular: Myocardial depression, vasodilation (septic shock), increased cardiac events (PMID: 25355293)

---

Clinical Presentation

Symptoms

Acute symptoms (below 7 days):

• Cough (80-90%) - Initially dry, then productive with purulent sputum (PMID: 29278410)
• Fever (70-80%) - Temperature greater than 38°C, rigors common in pneumococcal pneumonia
• Dyspnoea (60-70%) - Exertional or at rest depending on severity
• Pleuritic chest pain (40-50%) - Sharp, localized, worse with inspiration/cough (PMID: 24797699)
• Sputum production (50-70%) - Purulent, rusty (pneumococcus), or blood-tinged

Associated symptoms:

• Systemic: Myalgia, headache, fatigue, malaise (especially atypical pathogens)
• Gastrointestinal: Nausea, vomiting (20-30%), diarrhoea (15-20%, especially Legionella)
• Neurological: Confusion (10-20%, higher in elderly), delirium (PMID: 21048110)

Atypical presentations:

• Elderly: Confusion, falls, decompensation of chronic disease without fever/cough (PMID: 25520247)
• Immunosuppressed: Minimal symptoms despite severe radiographic changes
• COPD: Difficult to distinguish from acute exacerbation

Signs

Vital signs:

• Fever: Temperature greater than 38°C (70-80% of cases)
• Tachycardia: Heart rate greater than 100 bpm
• Tachypnoea: Respiratory rate greater than 20 breaths/min (greater than 24 indicates severity)
• Hypotension: SBP below 90 mmHg or MAP below 65 mmHg (severe CAP/septic shock)
• Hypoxaemia: SpO₂ below 90% on room air (requires admission)

Respiratory examination:

• Inspection: Use of accessory muscles, cyanosis (severe), reduced chest expansion (lobar consolidation)
• Palpation: Increased tactile vocal fremitus over consolidation
• Percussion: Dullness over consolidation or effusion
• Auscultation:
  • Crackles/crepitations (70-80%) - Fine inspiratory crackles over affected lobe
  • Bronchial breathing (20-30%) - Harsh, tubular breath sounds over consolidation
  • Pleural rub (10-15%) - Coarse, creaking sound suggesting pleuritis
  • Reduced air entry (30-40%) - Effusion or severe consolidation

Extrapulmonary signs:

• Confusion/delirium (10-20%) - Marker of severity, especially in elderly (PMID: 21048110)
• Cyanosis - Central cyanosis indicates severe hypoxaemia
• Herpes labialis (5-10%) - Classically associated with pneumococcal pneumonia

---

Investigations

Mandatory Investigations

Chest X-ray (posteroanterior and lateral):

• Lobar consolidation (40-50%) - Homogeneous opacity confined to a lobe, air bronchograms (PMID: 29278410)
• Bronchopneumonia/patchy infiltrates (30-40%) - Multifocal, bilateral, peribronchial distribution
• Interstitial infiltrates (15-20%) - Reticular or ground-glass pattern (atypical pathogens, viruses)
• Pleural effusion (20-40%) - Blunting of costophrenic angle; sample if greater than 1cm on lateral decubitus
• Cavitation (2-5%) - S. aureus, anaerobes, Klebsiella, TB (PMID: 24797699)
• Multilobar involvement (10-20%) - Marker of severity, associated with higher mortality

Diagnostic yield:

• 70-80% sensitivity (PMID: 33289525)
• Normal CXR in 10-20% early pneumonia (especially dehydration, neutropenia, Pneumocystis)
• Repeat CXR in 24-48h if high clinical suspicion and initial CXR normal

Oxygen saturation (pulse oximetry):

• SpO₂ below 90% on room air = severe CAP requiring admission
• SpO₂ below 92% in COPD or chronic lung disease warrants concern
• ABG if SpO₂ below 92% or signs of respiratory failure (PMID: 29278410)

Blood tests:

• Full blood count: Leukocytosis (greater than 10×10⁹/L) or leukopenia (below 4×10⁹/L in severe sepsis)
• CRP: greater than 100 mg/L suggests bacterial pneumonia; below 50 mg/L may indicate viral
• Urea and creatinine: Elevated urea (greater than 7 mmol/L) part of CURB-65 score
• Electrolytes: Hyponatraemia (below 130 mmol/L) in Legionella, SIADH (PMID: 24797699)
• Liver function tests: Elevated in sepsis, atypical pathogens
• Lactate: greater than 2 mmol/L indicates tissue hypoperfusion/sepsis (PMID: 28114553)

Microbiological Investigations

Indicated for:

• CURB-65 ≥2 (hospitalized patients)
• Severe CAP (ICU admission, respiratory failure, septic shock)
• Failed outpatient antibiotics
• Cavitation or suspicion of resistant pathogens (PMID: 33289525)

Blood cultures (2 sets from different sites):

• Positive in 5-15% of hospitalized CAP (PMID: 29278410)
• Higher yield in pneumococcal bacteraemia (25-30%)
• Obtain before antibiotics if possible, but do not delay treatment

Sputum culture (if productive cough):

• Pre-treatment sample (within 4 hours of antibiotics)
• Quality: greater than 25 neutrophils, below 10 squamous cells per low-power field
• Yield: 40-60% if good quality sputum obtained (PMID: 24797699)
• Gram stain may guide early therapy (Gram-positive diplococci = S. pneumoniae)

Urine antigen tests:

• Pneumococcal urinary antigen (sensitivity 70-80%, specificity greater than 95%) (PMID: 24797699)
  • Detects capsular polysaccharide
  • Remains positive for weeks (cannot assess treatment response)
  • "False positives: Nasopharyngeal colonization in children"
• Legionella urinary antigen (sensitivity 70-80% for L. pneumophila serogroup 1, specificity greater than 99%) (PMID: 20920453)
  • Only detects serogroup 1 (80% of cases)
  • Indicated if severe CAP, travel, water exposure, hyponatraemia, diarrhoea

Respiratory viral PCR panel:

• Influenza A/B, SARS-CoV-2, RSV, parainfluenza, adenovirus, human metapneumovirus
• Nasopharyngeal swab - Rapid result (1-2 hours)
• Positive in 15-30% of adult CAP (PMID: 33289525)
• Changes management: Oseltamivir for influenza, isolation for SARS-CoV-2, avoids unnecessary antibiotics

Advanced Investigations (Selected Cases)

Pleural fluid sampling (thoracentesis):

• Indications: Effusion greater than 1cm on lateral decubitus CXR, suspected empyema
• Empyema indicators: pH below 7.2, glucose below 2.2 mmol/L, LDH greater than 1,000 U/L, positive Gram stain/culture (PMID: 23997176)
• Send for: Cell count, protein, LDH, pH, glucose, Gram stain, culture, cytology if malignancy suspected

CT chest (contrast-enhanced):

• Indications: Non-resolving pneumonia (persistent fever/infiltrate after 72h antibiotics), suspected complication (abscess, empyema), underlying malignancy/obstruction, immunocompromised (PMID: 29278410)
• Findings: Cavitation, abscess, necrotizing pneumonia, mediastinal lymphadenopathy, endobronchial lesion

Bronchoscopy with bronchoalveolar lavage (BAL):

• Indications: Immunocompromised, non-resolving pneumonia, suspected TB/fungal infection, ventilated patients with severe CAP (PMID: 24797699)
• Yield: Higher in immunocompromised (40-60%) vs immunocompetent (20-30%)

---

Severity Assessment

CURB-65 Score

Bedside severity score validated for CAP (PMID: 12728059):

Score interpretation:

• 0-1: Low risk (1-3% mortality) - Consider outpatient management
• 2: Moderate risk (9-15% mortality) - Hospital admission recommended
• ≥3: High risk (15-40% mortality) - Urgent hospital admission, consider ICU

Limitations:

• Does not account for hypoxaemia, comorbidities, or social factors
• Age criterion penalizes elderly but may under-triage young patients with severe CAP

Pneumonia Severity Index (PSI) / PORT Score

More complex 20-variable risk stratification tool (PMID: 8995086):

Class I: Age below 50, no comorbidities, normal vital signs → Outpatient (mortality below 1%)

Class II-III (PSI score 51-90): Low-moderate risk → Consider brief observation or home with follow-up (mortality 1-3%)

Class IV (PSI 91-130): Moderate-high risk → Hospital admission (mortality 8-15%)

Class V (PSI greater than 130): High risk → Hospital admission, consider ICU (mortality greater than 25%)

Advantages: Better negative predictive value (identifies very low-risk patients)

Disadvantages: Complex calculation, requires age and comorbidity data, less practical in ED

ICU Admission Criteria

IDSA/ATS Major Criteria (1 required):

1. Invasive mechanical ventilation required
2. Septic shock requiring vasopressors (PMID: 31573637)

IDSA/ATS Minor Criteria (≥3 required):

1. Respiratory rate ≥30 breaths/min
2. PaO₂/FiO₂ ratio ≤250
3. Multilobar infiltrates
4. Confusion/disorientation
5. Uraemia (BUN ≥20 mg/dL)
6. Leukopenia (WBC below 4×10⁹/L)
7. Thrombocytopenia (platelets below 100×10⁹/L)
8. Hypothermia (core temperature below 36°C)
9. Hypotension requiring aggressive fluid resuscitation

SMART-COP Score (Australian tool): Predicts need for intensive respiratory or vasopressor support (PMID: 18182439):

• S - SBP below 90 mmHg (2 points)
• M - Multilobar CXR infiltrates (1 point)
• A - Albumin below 35 g/L (1 point)
• R - Respiratory rate (age ≤50: RR ≥25 = 1 point; age greater than 50: RR ≥30 = 1 point)
• T - Tachycardia ≥125 bpm (1 point)
• C - Confusion (1 point)
• O - Oxygenation (age ≤50: PaO₂ below 70 or SpO₂ ≤93% = 2 points; age greater than 50: PaO₂ below 60 or SpO₂ ≤90% = 2 points)
• P - pH below 7.35 (2 points)

Score ≥3 indicates high risk for ICU admission or death.

---

Management

Initial Resuscitation (First 60 minutes)

A - Airway:

• Protect airway if GCS ≤8 or copious secretions
• Consider intubation if hypoxaemic respiratory failure despite high-flow oxygen (PMID: 29278410)

B - Breathing:

• Oxygen therapy: Target SpO₂ 92-96% (or 88-92% in COPD with risk of hypercapnia)
• Titrate oxygen delivery:
  • Nasal prongs 1-6 L/min (FiO₂ 24-40%)
  • Simple face mask 6-10 L/min (FiO₂ 40-60%)
  • Non-rebreather mask 10-15 L/min (FiO₂ 60-90%)
  • High-flow nasal cannula (HFNC) 30-60 L/min (FiO₂ up to 100%)
• Non-invasive ventilation (NIV): Consider in hypercapnic respiratory failure (Type II), but not superior to HFNC in hypoxaemic failure (PMID: 25981908)
• Intubation criteria: Apnoea, refractory hypoxaemia (PaO₂ below 60 mmHg on FiO₂ greater than 0.6), hypercapnia (PaCO₂ greater than 60 mmHg with pH below 7.25), exhaustion, decreased GCS

C - Circulation:

• IV access: Two large-bore cannulas if signs of sepsis
• Fluid resuscitation: 500mL crystalloid bolus if hypotensive (SBP below 90 mmHg) or lactate greater than 2 mmol/L (PMID: 28114553)
• Fluid responsiveness: Reassess after each bolus (target MAP ≥65 mmHg, urine output greater than 0.5 mL/kg/h)
• Vasopressors: Noradrenaline infusion if MAP below 65 mmHg despite 30 mL/kg fluid resuscitation (septic shock)

D - Disability:

• Assess GCS, confusion (CURB-65 criterion)
• Hypoglycaemia or hypoxaemia can cause confusion

E - Exposure:

• Full examination for source of sepsis, skin rashes (e.g., meningococcal coinfection)

Antibiotic Therapy

Timing:

• Antibiotics within 1 hour of ED presentation for severe CAP/sepsis (PMID: 29278410)
• Within 4 hours for non-severe CAP

Empirical regimens (Therapeutic Guidelines Australia):

(PMID: 31573637, 33289525)

Rationale for combination therapy:

• β-lactam + macrolide: Synergistic activity, covers typical + atypical pathogens, anti-inflammatory properties of macrolides (PMID: 18182439)
• Dual therapy reduces mortality in severe CAP (30-day mortality 10% vs 15% monotherapy) (PMID: 18182439)

Special situations:

(PMID: 24797699, 29278410)

De-escalation:

• Switch IV to oral antibiotics when clinically stable (temperature below 37.8°C, HR below 100, RR below 24, SBP greater than 90, tolerating oral intake)
• Typically after 48-72 hours IV therapy
• Narrow spectrum based on culture results (PMID: 33289525)

Adjunctive Therapy

Corticosteroids:

• Not routinely recommended in CAP (PMID: 25539614)
• Consider in refractory septic shock: Hydrocortisone 50mg IV Q6H or 200mg/day infusion if requiring high-dose vasopressors (PMID: 28114553)
• May reduce time to clinical stability but no mortality benefit and increased hyperglycaemia risk (PMID: 25539614)

Antivirals:

• Oseltamivir 75mg PO BD for 5 days if influenza PCR positive (PMID: 31573637)
• Start within 48 hours of symptom onset (greatest benefit)
• Consider in severe CAP during influenza season even if greater than 48h if critically ill

Thromboprophylaxis:

• Enoxaparin 40mg SC daily or unfractionated heparin 5,000 units SC Q8-12H for all hospitalized patients unless contraindicated (PMID: 33289525)
• High risk of VTE in immobile pneumonia patients

Physiotherapy:

• Early mobilization to prevent deconditioning and VTE
• Incentive spirometry may reduce atelectasis

---

Disposition

Admission Criteria

Hospital admission recommended if:

• CURB-65 ≥2 (or PSI Class IV-V)
• Hypoxaemia (SpO₂ below 90% on room air)
• Severe tachypnoea (RR greater than 30)
• Hypotension (SBP below 90 mmHg)
• Multilobar pneumonia
• Cavitation or complicated pneumonia (effusion, empyema)
• Inability to tolerate oral intake or medications
• Unstable comorbidities (e.g., exacerbation of heart failure, COPD, diabetes)
• Social factors (homelessness, inability to self-care, lack of follow-up)

(PMID: 29278410, 33289525)

ICU admission if:

• Septic shock requiring vasopressors
• Respiratory failure requiring mechanical ventilation
• ≥3 minor IDSA/ATS criteria or 1 major criterion (PMID: 31573637)

Discharge Criteria

Clinical stability (all required):

1. Temperature ≤37.8°C
2. Heart rate ≤100 bpm
3. Respiratory rate ≤24 breaths/min
4. Systolic blood pressure ≥90 mmHg
5. Oxygen saturation ≥90% on room air
6. Ability to maintain oral intake
7. Normal mental status

(PMID: 21048110)

Outpatient discharge safe if:

• CURB-65 0-1
• No hypoxaemia (SpO₂ greater than 90% on room air)
• Tolerating oral antibiotics
• Reliable for follow-up
• Adequate social support

Discharge instructions:

• Antibiotics: Complete full course (5 days minimum)
• Follow-up: GP review in 48-72 hours
• Return precautions: Worsening dyspnoea, chest pain, confusion, inability to tolerate oral intake
• Smoking cessation: All smokers should receive brief intervention and Quitline referral (PMID: 25520247)
• Follow-up CXR: Repeat CXR in 6 weeks to confirm resolution (exclude underlying malignancy, especially age greater than 50, smokers)

---

Complications

Early Complications (0-7 days)

Respiratory failure:

• Hypoxaemic (Type I): V/Q mismatch, shunt
• Hypercapnic (Type II): Respiratory muscle fatigue, COPD exacerbation
• Management: Oxygen therapy, NIV, intubation if refractory

Septic shock:

• 10-15% of hospitalized CAP develops septic shock (PMID: 28114553)
• Mortality 30-50%
• Management: Fluid resuscitation, vasopressors (noradrenaline), broad-spectrum antibiotics, lactate monitoring

Pleural effusion:

• Develops in 20-40% of CAP (PMID: 23997176)
• Uncomplicated parapneumonic effusion: Small, free-flowing, pH greater than 7.2 → Antibiotics alone
• Complicated parapneumonic effusion: pH 7.0-7.2, LDH greater than 1,000, glucose below 2.2 → Chest drain + antibiotics
• Empyema: Pus, pH below 7.0, positive Gram stain/culture → Chest drain + antibiotics ± VATS decortication (PMID: 23997176)

Acute kidney injury:

• Sepsis-induced ATN, pre-renal (dehydration), drug-induced (NSAIDs, aminoglycosides)
• Monitor urea, creatinine, urine output
• Ensure adequate hydration

Cardiac events:

• Acute MI, heart failure, arrhythmias (AF)
• 5-10% of CAP patients experience cardiac event within 30 days (PMID: 25355293)
• Inflammatory stress, hypoxaemia, increased myocardial oxygen demand

Late Complications (greater than 7 days)

Lung abscess:

• Occurs in 2-5% of CAP, especially aspiration pneumonia (PMID: 24797699)
• CXR/CT: Thick-walled cavity with air-fluid level
• Pathogens: Anaerobes, S. aureus, Klebsiella
• Treatment: Prolonged antibiotics (4-6 weeks), percutaneous or surgical drainage if greater than 4cm

Organizing pneumonia (COP):

• Persistent infiltrates and systemic symptoms despite antibiotics
• CT: Patchy consolidation, "reverse halo sign"
• Diagnosis: Transbronchial or surgical lung biopsy
• Treatment: Corticosteroids (prednisolone 0.75-1 mg/kg/day)

Post-infectious bronchiolitis obliterans:

• Rare, progressive dyspnoea after pneumonia (especially adenovirus, Mycoplasma)
• PFTs: Obstructive pattern
• CT: Mosaic attenuation, bronchial wall thickening

Necrotizing pneumonia:

• Extensive lung necrosis with multiple small cavities
• Pathogens: S. aureus (PVL toxin), S. pneumoniae serotype 3, K. pneumoniae
• High mortality (20-40%)
• Management: Prolonged antibiotics, surgical debridement if refractory (PMID: 31573637)

---

Non-Resolving Pneumonia

Definition: Failure to improve clinically or radiographically after 72 hours of appropriate antibiotics (PMID: 29278410)

Incidence: 10-15% of hospitalized CAP

Causes

Infectious:

• Resistant pathogens: MRSA, ESBL-producing Gram-negatives, Pseudomonas
• Uncommon pathogens: TB, fungi (Aspergillus, Histoplasma), Nocardia, Pneumocystis
• Inadequate source control: Empyema, abscess

Non-infectious:

• Malignancy: Endobronchial tumour, lymphangitis carcinomatosis
• Pulmonary embolism: Mimics pneumonia, coexistent
• Organizing pneumonia (COP)
• Vasculitis: Granulomatosis with polyangiitis, eosinophilic granulomatosis
• Drug reaction: Drug-induced pneumonitis

Host factors:

• Immunosuppression: HIV, chemotherapy, corticosteroids
• Structural lung disease: Bronchiectasis, COPD, post-obstructive pneumonia

Evaluation

Reassess history:

• Travel (TB, endemic fungi), occupational exposures, immunosuppression, recent antibiotics

Investigations:

• CT chest (contrast): Cavitation, abscess, empyema, malignancy, PE
• Bronchoscopy + BAL: Microbiology (TB, fungi, atypical bacteria), cytology (malignancy)
• Sputum for TB (3 samples): AFB smear, TB culture, GeneXpert
• Serology: Legionella, Mycoplasma, HIV
• Autoimmune screen: ANA, ANCA, anti-GBM if vasculitis suspected

Management:

• Broaden antibiotics if resistant pathogens suspected
• Drainage of empyema/abscess
• Treat underlying cause (malignancy, TB, fungi)

---

Special Populations

Elderly (Age greater than 65)

Epidemiology:

• Incidence 25-35 per 1,000 per year (PMID: 21048110)
• 30-day mortality 10-20% (double that of younger adults)

Atypical presentation:

• Confusion/delirium (30-40%) more common than fever
• Falls, functional decline, reduced oral intake
• Lower fever response (20-30% afebrile)

Pathogens:

• Higher incidence of Gram-negative bacilli (E. coli, Klebsiella)
• Aspiration pneumonia more common (dysphagia, stroke, dementia)

Management:

• Lower threshold for admission (CURB-65 penalizes age)
• Monitor for delirium, cardiac events
• Early mobilization, nutritional support

Pregnancy

Considerations:

• Physiological changes: Increased oxygen consumption, reduced functional residual capacity, relative immunosuppression
• Higher risk of severe CAP and respiratory failure
• Increased maternal and fetal morbidity/mortality

Pathogens: Similar to non-pregnant adults

Antibiotics (Category B):

• Preferred: Amoxicillin-clavulanate 875/125mg PO BD + azithromycin 500mg PO daily
• Avoid: Fluoroquinolones (cartilage toxicity), tetracyclines (teeth discoloration), trimethoprim (folate antagonist)

Imaging:

• CXR safe with abdominal shielding (below 0.01 mGy fetal dose)

Admission threshold: Lower (consider admission if CURB-65 ≥1)

Immunocompromised

Risk factors:

• HIV (CD4 below 200 cells/μL)
• Chemotherapy-induced neutropenia
• Corticosteroids (greater than 20mg prednisone greater than 2 weeks)
• Biologic agents (anti-TNF, rituximab)
• Solid organ or haematopoietic stem cell transplant

Pathogens:

• Typical bacterial pathogens (still most common)
• Opportunistic: Pneumocystis jirovecii, Aspergillus, Cryptococcus, CMV, Nocardia, atypical mycobacteria

Investigations:

• Bronchoscopy + BAL often required (yield 40-60%)
• Sputum for PCP (induced sputum if not productive)
• Serum/BAL galactomannan (Aspergillus)
• (1-3)-β-D-glucan (Pneumocystis, Aspergillus, Candida)

Empirical antibiotics:

• Broad-spectrum: Piperacillin-tazobactam 4.5g IV Q6H + azithromycin 500mg IV daily
• Add if CD4 below 200 or PCP risk: Trimethoprim-sulfamethoxazole 5mg/kg (TMP) IV Q6H + prednisone 40mg BD (if PaO₂ below 70 mmHg)

---

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Health

Epidemiology:

• 3-5x higher incidence of CAP (PMID: 30760144)
• 2-3x higher mortality from respiratory infections (PMID: 26040576)
• Younger age of presentation (median age 50 vs 65 in non-Indigenous)

Risk factors:

• Higher smoking rates (40-50% vs 12-15% non-Indigenous)
• Chronic lung disease: COPD, bronchiectasis rates 3-4x higher (PMID: 28691157)
• Comorbidities: Diabetes (20-30%), chronic kidney disease (10-15%), cardiovascular disease
• Socioeconomic factors: Overcrowding (increased transmission), remote location (delayed presentation), food insecurity

Pathogens:

• Standard CAP pathogens
• Consider melioidosis (Burkholderia pseudomallei) in northern Australia during wet season (PMID: 30335017)

Cultural considerations:

• Family-centred care: Involve Aboriginal Health Workers, allow family presence
• Communication: Use professional interpreters for language barriers, plain language, visual aids
• Cultural safety: Respect kinship systems, traditional healing practices, spiritual beliefs
• Discharge planning: Ensure culturally safe follow-up, consider transport barriers, involve Aboriginal Medical Services

Remote/rural challenges:

• Delayed presentation: Average 3-5 days from symptom onset (vs 1-2 days urban)
• Limited resources: No CT, limited pathology, intermittent X-ray availability
• Retrieval considerations: RFDS retrieval if severe CAP, ICU requirement (PMID: 29541571)
• Telemedicine: Virtual ED or specialist consultation for clinical guidance

Māori and Pacific Peoples (New Zealand)

Epidemiology:

• 2-3x higher hospitalization rates for CAP
• Higher burden of pneumococcal disease despite vaccination programs (PMID: 24933391)

Risk factors:

• Socioeconomic deprivation (disproportionate representation in lower quintiles)
• Overcrowding, cold/damp housing
• Higher smoking rates
• Cardiovascular disease, diabetes, chronic kidney disease

Cultural considerations:

• Whānau (extended family) involvement: Key decision-makers, provide psychosocial support
• Te reo Māori: Offer interpreter services if preferred language
• Tikanga (customs): Respect cultural protocols (e.g., karakia/prayer)
• Manaakitanga (care and hospitality): Holistic approach, address social determinants

---

Remote and Rural Emergency Medicine

Challenges in Resource-Limited Settings

Diagnostic limitations:

• CXR may not be available 24/7 (relies on visiting radiographer or telemedicine)
• No CT scanning (nearest CT may be 200-500 km away)
• Limited pathology services (blood cultures may need transport to regional lab)

Clinical approach:

• High reliance on clinical diagnosis: History, examination, bedside vitals
• Oxygen saturation: Critical triage tool (SpO₂ below 90% = severe CAP)
• Lactate and CRP: Point-of-care testing may guide severity assessment

Management:

• Empirical antibiotics: Cannot wait for microbiology; treat based on CURB-65
• IV antibiotics: May need to initiate IV therapy even if outpatient in urban setting
• Observation period: Short-stay unit or 24h observation to assess response

Retrieval Medicine

Indications for RFDS retrieval:

• Severe CAP with CURB-65 ≥3 or ICU criteria (PMID: 29541571)
• Respiratory failure requiring mechanical ventilation
• Septic shock requiring vasopressors
• Complicated pneumonia (empyema requiring drainage)

Pre-retrieval stabilization:

• Secure airway (intubate if GCS ≤8 or severe hypoxaemia)
• Oxygen therapy (portable oxygen concentrators, backup cylinders)
• IV antibiotics (administer before flight)
• IV fluids and vasopressors if septic shock
• Analgesia for pleuritic pain

Communication:

• Contact RFDS coordination centre (1800 625 800)
• Telemedicine consultation with retrieval physician
• Handover to receiving ICU/ED team

Aeromedical considerations:

• Decreased PaO₂ at altitude (cabin pressure equivalent to 2,400m)
• Pneumothorax risk (expansion of gas in pleural space at altitude; drain before flight)
• Monitor for decompensation during flight

---

ACEM Viva Practice

Viva Scenario 1: Severe CAP with Septic Shock

Stem: A 72-year-old woman with a history of COPD presents to your ED with 3 days of worsening cough, fever, and dyspnoea. She is confused, tachypnoeic at 32 breaths/min, hypotensive with BP 85/50 mmHg, HR 120 bpm, SpO₂ 88% on room air. Her partner reports she has had minimal oral intake for 2 days.

Opening Question: What are your immediate management priorities?

Model Answer: This is severe community-acquired pneumonia complicated by septic shock. My immediate priorities follow an ABCDE approach:

A - Airway: Assess airway patency; she is talking so airway is patent, but given her confusion (GCS likely reduced) I would have suction and airway adjuncts ready.

B - Breathing:

• Apply high-flow oxygen via non-rebreather mask targeting SpO₂ 92-96% (or 88-92% given COPD)
• Obtain ABG to assess oxygenation, ventilation (hypercapnia risk in COPD), and lactate
• Auscultate chest for consolidation/effusion
• Portable CXR to confirm pneumonia

C - Circulation:

• Secure two large-bore IV cannulas
• Take blood cultures (2 sets from different sites) before antibiotics
• Administer 500mL crystalloid bolus rapidly (within 15 minutes)
• Reassess BP, HR, perfusion after bolus; repeat boluses targeting MAP ≥65 mmHg
• If remains hypotensive after 30 mL/kg fluids, commence noradrenaline infusion
• Send blood tests: FBC, UEC, CRP, LFT, coagulation, lactate

D - Disability: Assess GCS and blood glucose (hypoglycaemia can cause confusion)

E - Exposure: Full examination, check for rashes, other sources of sepsis

Antibiotics within 1 hour:

• Severe CAP with septic shock: Benzylpenicillin 2.4g IV Q4H (or ceftriaxone 2g IV daily) + azithromycin 500mg IV daily
• Consider broader coverage if risk factors for resistant pathogens (recent antibiotics, nursing home)

Follow-up Question: Her CURB-65 score is 5. What does this mean for her prognosis and disposition?

Model Answer: CURB-65 score 5 (maximum score) indicates:

• C - Confusion (present - disoriented)
• U - Urea likely greater than 7 mmol/L (dehydration, pre-renal AKI from sepsis)
• R - Respiratory rate 32 (greater than 30)
• B - Blood pressure 85/50 (SBP below 90)
• 65 - Age 72 (greater than 65)

Prognosis: This score predicts 15-40% mortality risk. Her septic shock further increases this to 30-50%.

Disposition:

• ICU admission required for septic shock management (vasopressor support)
• Early ICU referral to discuss intubation if respiratory failure worsens despite high-flow oxygen
• Consider non-invasive ventilation if hypercapnic (BiPAP) but may not tolerate if confused
• Goals of care discussion with family given high mortality risk

Follow-up Question: After 30 mL/kg fluid resuscitation her BP is 92/55, MAP 67 mmHg. What is your next step?

Model Answer: She has achieved target MAP ≥65 mmHg with fluid resuscitation alone, so I would:

1. Reassess fluid responsiveness: Check for signs of volume overload (crackles, JVP, peripheral oedema)
2. Monitor closely: Continuous BP monitoring, urine output (target greater than 0.5 mL/kg/h)
3. Repeat lactate in 2-6 hours to assess clearance (greater than 10% reduction or normalization indicates resuscitation success)
4. Avoid further fluid boluses unless signs of hypovolaemia recur
5. ICU admission for close haemodynamic monitoring and potential vasopressor requirement

If MAP drops below 65 mmHg despite adequate fluid resuscitation, I would commence noradrenaline infusion titrated to MAP ≥65 mmHg.

---

Viva Scenario 2: CAP in Pregnancy

Stem: A 28-year-old woman at 32 weeks gestation presents with 2 days of fever, cough productive of purulent sputum, and left-sided pleuritic chest pain. She has no significant past medical history. Vitals: T 38.7°C, HR 105 bpm, BP 118/72 mmHg, RR 22 breaths/min, SpO₂ 94% on room air.

Opening Question: How does pregnancy alter your assessment and management of CAP?

Model Answer:

Physiological changes in pregnancy:

1. Increased oxygen consumption (20-30%) and reduced functional residual capacity → faster desaturation
2. Relative immunosuppression → increased susceptibility to severe infection
3. Increased tidal volume → respiratory alkalosis (normal pH 7.42-7.47, PaCO₂ 28-32 mmHg)
4. Physiological anaemia (haemodilution) → reduced oxygen-carrying capacity

Assessment:

• Lower threshold for concern: SpO₂ 94% is borderline (I would target ≥95% in pregnancy)
• CURB-65 score: She scores 0 (no confusion, urea likely normal, RR 22, BP normal, age 28), but pregnancy is not accounted for in CURB-65
• Fetal monitoring: Continuous CTG monitoring to assess fetal wellbeing (tachycardia may indicate maternal hypoxia or infection)

Investigations:

• CXR: Safe with abdominal shielding (fetal dose below 0.01 mGy, far below teratogenic threshold of 100 mGy)
• Blood tests: FBC, UEC, CRP, blood cultures
• Sputum culture if productive
• Urine pneumococcal antigen

Management:

Oxygen: High-flow oxygen to maintain SpO₂ ≥95%

Antibiotics (Category B1 - safe in pregnancy):

• Amoxicillin-clavulanate 875/125mg PO BD (covers typical bacteria + aspiration risk)
• PLUS azithromycin 500mg PO daily (covers atypical pathogens)
• Avoid: Fluoroquinolones, tetracyclines, trimethoprim (especially first trimester)

Disposition:

• Lower threshold for admission given pregnancy (even though CURB-65 is 0)
• Admit for observation, IV fluids, fetal monitoring
• Involve obstetrics team for fetal assessment
• Monitor for preterm labour (infection is a trigger)

Follow-up Question: She deteriorates with SpO₂ 88% on 15L via non-rebreather mask. What are your concerns and next steps?

Model Answer: This is acute hypoxaemic respiratory failure in pregnancy - a life-threatening emergency for both mother and fetus.

Immediate concerns:

1. Maternal: Severe CAP with impending respiratory failure; ARDS risk
2. Fetal: Hypoxia causing fetal distress, risk of preterm delivery, stillbirth

Management:

1. Escalate oxygen therapy: Trial of high-flow nasal cannula (HFNC 60L/min, FiO₂ 100%)
2. Prepare for intubation: Obstetric airway (full stomach risk, reduced FRC, difficult intubation in pregnancy)
   • Call anaesthetics urgently
   • Rapid sequence intubation with smaller ETT (6.5-7.0mm) due to airway oedema
3. ICU consultation for mechanical ventilation
4. Obstetric consultation urgently:
   • CTG monitoring for fetal distress
   • Discuss timing of delivery (maternal resuscitation prioritized first; consider emergency caesarean if fetus viable greater than 24 weeks and maternal condition critical)
5. Upgrade antibiotics: IV benzylpenicillin 2.4g Q4H + azithromycin 500mg IV daily (severe CAP)
6. Positioning: Left lateral tilt to reduce aortocaval compression (improves maternal venous return and fetal perfusion)

Key principle: Maternal resuscitation is the priority; optimal management of the mother is the best intervention for the fetus.

---

Viva Scenario 3: Non-Resolving Pneumonia

Stem: A 55-year-old man was admitted 5 days ago with left lower lobe pneumonia (CURB-65 score 2). He was treated with IV amoxicillin and azithromycin. Despite antibiotics, he remains febrile (38.5°C), dyspnoeic, and has ongoing productive cough. Repeat CXR shows persistent left lower lobe consolidation with a new moderate pleural effusion.

Opening Question: What are your differential diagnoses for non-resolving pneumonia?

Model Answer:

Non-resolving pneumonia is defined as failure to improve clinically or radiographically after 72 hours of appropriate antibiotics. The differential includes:

Infectious causes:

1. Resistant or unusual pathogens:
   • MRSA, ESBL Gram-negatives, Pseudomonas aeruginosa
   • Atypical: Legionella (slow response), Mycoplasma
   • TB, fungi (Aspergillus, endemic fungi), Nocardia
   • Pneumocystis jirovecii (if immunocompromised)
2. Inadequate source control:
   • Complicated parapneumonic effusion or empyema
   • Lung abscess

Non-infectious causes:

1. Malignancy: Endobronchial tumour causing post-obstructive pneumonia, lymphangitis carcinomatosis
2. Pulmonary embolism (can mimic or coexist with pneumonia)
3. Organizing pneumonia (COP)
4. Vasculitis: Granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis (EGPA)
5. Drug-induced pneumonitis

Host factors:

• Immunosuppression (HIV, corticosteroids, chemotherapy)
• Structural lung disease (bronchiectasis, COPD)

Follow-up Question: What investigations would you order?

Model Answer:

Immediate investigations:

1. Pleural fluid sampling (diagnostic and therapeutic thoracentesis):

   • Indications: Effusion greater than 1cm on lateral decubitus CXR or ultrasound
   • Send for:
     • Appearance: Turbid/purulent suggests empyema
     • Cell count and differential
     • Protein, LDH, glucose (Light's criteria for exudate vs transudate)
     • pH (pH below 7.2 indicates complicated effusion; below 7.0 = empyema)
     • Gram stain and culture (aerobic, anaerobic, TB, fungi)
     • Cytology (if malignancy suspected)
   • Empyema criteria (≥1 required):
     • Pus on aspiration
     • Positive Gram stain or culture
     • pH below 7.2
     • Glucose below 2.2 mmol/L, LDH greater than 1,000 U/L

2. CT chest (contrast-enhanced):

   • Assess for lung abscess, cavitation, necrotizing pneumonia
   • Endobronchial lesion (malignancy)
   • Mediastinal/hilar lymphadenopathy
   • Pulmonary embolism (CTPA protocol)

3. Bronchoscopy + bronchoalveolar lavage (BAL):

   • Indications: Immunocompromised, suspected TB/fungal infection, no microbiological diagnosis
   • Send BAL for: TB (AFB smear, culture, GeneXpert), fungal culture, Pneumocystis PCR, viral PCR, bacterial culture, cytology

4. Extended microbiology:

   • Sputum for TB (3 samples for AFB smear, culture, GeneXpert)
   • Serology: HIV, Legionella, Mycoplasma
   • Urine: Legionella and pneumococcal antigens (if not done initially)
   • Blood cultures (repeat)

5. Autoimmune screen (if vasculitis suspected):

   • ANCA, ANA, anti-GBM, rheumatoid factor

Follow-up Question: Thoracentesis yields turbid fluid with pH 7.1, glucose 1.5 mmol/L, LDH 1,200 U/L, Gram stain shows Gram-positive cocci in chains. What is your diagnosis and management?

Model Answer:

Diagnosis: Empyema (complicated parapneumonic effusion with positive Gram stain, pH below 7.2, glucose below 2.2 mmol/L, elevated LDH). Gram-positive cocci in chains suggest Streptococcus species (likely S. pneumoniae or Streptococcus anginosus group).

Management:

1. Chest drain insertion:

   • Indication: Empyema requires drainage (PMID: 23997176)
   • Ultrasound-guided large-bore chest drain (≥14 Fr) in safe triangle
   • Monitor output: Aim for below 50mL/day before removal

2. Antibiotics:

   • Upgrade to broader coverage for empyema:
     • IV amoxicillin-clavulanate 1.2g Q8H or piperacillin-tazobactam 4.5g Q8H (covers anaerobes)
     • Duration: 3-6 weeks total (2-4 weeks IV, then switch to oral)
   • Adjust based on culture results (Gram-positive cocci likely Streptococcus)

3. Intrapleural fibrinolytics (if loculated):

   • Indication: Persistent sepsis despite drain, loculated effusion on CT/ultrasound
   • Regimen: Alteplase 10mg + DNase 5mg via chest drain BD for 3 days (MIST-2 protocol) (PMID: 21816485)

4. Surgical referral (thoracic surgery):

   • VATS decortication indicated if:
     • Failed medical management (persistent fever/sepsis after 5-7 days)
     • Thick pleural peel (trapped lung)
     • Organized empyema (stage III)

5. Supportive care:

   • Nutrition support (high catabolic state)
   • Thromboprophylaxis
   • Early mobilization

Prognosis: Empyema mortality 5-15%; higher if delayed treatment or comorbidities.

---

Viva Scenario 4: CAP in Remote Australia

Stem: You are working in a remote Northern Territory community (population 800, 400 km from nearest hospital). A 45-year-old Aboriginal man presents with 4 days of fever, productive cough with blood-tinged sputum, and right-sided pleuritic chest pain. He is a smoker with known diabetes. Vitals: T 39.1°C, HR 110 bpm, BP 105/65 mmHg, RR 28 breaths/min, SpO₂ 91% on room air. Your clinic has basic pathology (point-of-care glucose, Hb, WCC) and portable X-ray available once daily.

Opening Question: How does the remote setting alter your assessment and management?

Model Answer:

Assessment challenges:

1. Limited diagnostics:
   • Portable CXR once daily (wait for radiographer or telemedicine interpretation)
   • No CT, limited microbiology (blood cultures need transport to regional lab, may take 48-72h)
   • Point-of-care testing: Glucose, Hb, WCC, CRP (if available), lactate (if available)
2. Delayed presentation: 4 days of symptoms (vs 1-2 days in urban areas) due to distance and access barriers
3. High-risk population: Aboriginal Australian with diabetes and smoking (3-5x higher CAP risk and mortality)

Clinical approach:

• Rely on clinical diagnosis: History, examination, vital signs, SpO₂
• CURB-65 score:
  • C - Assess confusion (oriented to person, place, time?)
  • U - Cannot measure urea accurately (estimate risk based on dehydration, poor oral intake)
  • R - Respiratory rate 28 breaths/min = 0 points (threshold is ≥30)
  • B - BP 105/65 = 0 points
  • 65 - Age 45 = 0 points
  • "Estimated CURB-65: 0-1, but SpO₂ 91% is concerning"

Red flags:

• Haemoptysis: Consider severe pneumonia, TB (endemic in remote communities), or melioidosis
• SpO₂ 91%: Borderline hypoxaemia (would normally prompt admission in urban setting)
• Diabetes: Increased risk of complications, resistant pathogens

Management:

1. Oxygen therapy:

   • Nasal prongs 2-4 L/min targeting SpO₂ ≥92%
   • Portable oxygen concentrator (ensure backup cylinders available)

2. IV antibiotics (moderate-severe CAP given hypoxaemia):

   • Benzylpenicillin 1.2g IV Q6H + azithromycin 500mg IV daily
   • PLUS consider ceftriaxone 2g IV daily (covers melioidosis if northern Australia during wet season)
   • Rationale: Cannot wait for CXR or microbiology; treat empirically based on clinical severity

3. Investigations:

   • Point-of-care glucose: Optimize diabetes control
   • Portable CXR when available (confirm diagnosis, assess severity)
   • Blood cultures if available (transport to regional lab)
   • Sputum for TB (AFB smear, GeneXpert) given haemoptysis
   • Melioidosis screening: Blood culture, sputum culture (if wet season, recent cyclone, mud/soil exposure)

4. Observation:

   • Admit to clinic observation unit for 24-48h
   • Monitor vitals Q4H, SpO₂ continuous monitoring
   • Reassess for clinical deterioration

Follow-up Question: After 24 hours he remains febrile (38.8°C), SpO₂ has dropped to 88% on 4L oxygen, and he is now confused. CXR shows right middle and lower lobe consolidation. What are your next steps?

Model Answer: This is deteriorating severe CAP with worsening hypoxaemia and new confusion (CURB-65 now ≥3). He requires retrieval to a tertiary centre.

Immediate management:

1. Escalate oxygen therapy:

   • Increase to 6-10L via simple face mask or 15L via non-rebreather mask
   • Target SpO₂ ≥92% (may need to accept 88-90% if limited oxygen supply)

2. Reassess airway:

   • GCS assessment (confused = GCS 13-14 likely; if GCS ≤8 → intubation)
   • Prepare for intubation if GCS dropping or respiratory exhaustion

3. Fluid resuscitation:

   • IV access (two large-bore cannulas)
   • 500mL crystalloid bolus (reassess BP, perfusion)

4. Upgrade antibiotics:

   • Continue benzylpenicillin 1.2g IV Q6H + azithromycin 500mg IV
   • Ensure ceftriaxone 2g IV daily or meropenem 1g IV Q8H if melioidosis strongly suspected (northern Australia, wet season, severe CAP)

5. Contact RFDS for retrieval:

   • Phone 1800 625 800 (RFDS coordination centre)
   • Provide handover:
     • 45-year-old Aboriginal man, severe CAP with CURB-65 ≥3
     • SpO₂ 88% on 15L O₂, new confusion, multilobar pneumonia on CXR
     • Requires ICU admission for mechanical ventilation consideration
   • Pre-retrieval stabilization:
     • Secure airway if GCS ≤8 (intubate before flight; risk of hypoxaemia at altitude)
     • Continue IV antibiotics
     • Portable oxygen cylinders + backup supply

6. Cultural considerations:

   • Involve Aboriginal Health Worker: Liaise with family, cultural support
   • Family communication: Explain need for retrieval, involve family in decision-making
   • Traditional healing: Respect if family wishes to involve traditional healers alongside Western medicine

Destination: Nearest tertiary hospital with ICU (likely Darwin, Alice Springs, or Adelaide depending on location).

Follow-up Question: What are specific considerations for melioidosis in this context?

Model Answer:

Melioidosis (Burkholderia pseudomallei):

• Endemic: Northern Australia (Northern Territory, Far North Queensland), wet season (October-April), especially post-cyclone/flooding
• Risk factors: Diabetes (50-60% of cases), chronic kidney disease, Aboriginal Australians, occupational exposure (farmers, construction workers)
• Clinical features: Severe CAP, septicaemia, abscesses (lung, liver, spleen), high mortality (10-20% with treatment, 90% without)

Diagnosis:

• Blood cultures, sputum culture (Gram-negative bacillus, safety pin appearance)
• Imaging: Lung abscesses, multilobar pneumonia

Treatment:

• Intensive phase (10-14 days): IV meropenem 1g Q8H or ceftazidime 2g Q6H
• Eradication phase (3-6 months): Oral trimethoprim-sulfamethoxazole 160/800mg (2 DS tabs) BD
• DO NOT use: Gentamicin, ciprofloxacin (intrinsically resistant)

Key point: Empirical coverage for melioidosis should be considered in any diabetic patient in northern Australia with severe CAP during wet season.

---

ACEM OSCE Stations

OSCE Station 1: Respiratory Examination and Interpretation

Setting: Clinical examination area
Time: 11 minutes (8 min examination, 3 min discussion)
Scenario: You are asked to examine the respiratory system of a 58-year-old man who presented with cough and fever.

Actor Briefing:

• Male, 58 years old
• Simulated findings: Decreased chest expansion on right, dullness to percussion at right base, reduced air entry and bronchial breathing at right lower lobe, fine inspiratory crackles

Task: Perform a focused respiratory examination and present your findings to the examiner.

Marking Criteria:

Total: 17 marks

Pass Mark: 11/17

---

OSCE Station 2: Breaking Bad News - ICU Admission for CAP

Setting: ED consultation room
Time: 11 minutes
Scenario: You are the ED registrar. A 68-year-old woman with severe CAP and septic shock requires ICU admission and likely intubation. Her husband is waiting to speak with you.

Actor Briefing (Husband):

• Worried, anxious about his wife's condition
• Knows she has pneumonia but doesn't understand severity
• Concerned about prognosis ("Will she be okay?")
• Wants to know if he can see her before she goes to ICU

Task: Explain the severity of the illness, need for ICU admission and intubation, and answer the husband's concerns.

Marking Criteria:

Total: 21 marks

Pass Mark: 13/21

---

OSCE Station 3: Prescribing Antibiotics in Penicillin Allergy

Setting: ED clinical workstation
Time: 11 minutes
Scenario: A 62-year-old man presents with CAP (CURB-65 score 2). He has a documented penicillin allergy ("rash and swelling of lips 20 years ago"). You need to prescribe appropriate antibiotics.

Actor Briefing (Patient):

• Knows he is allergic to penicillin
• Can describe reaction: "My lips swelled up and I got a red itchy rash all over" after taking penicillin tablets for a chest infection 20 years ago
• Has not taken penicillin since
• Concerned about antibiotic allergy ("Will these antibiotics be safe for me?")

Task:

1. Take a focused allergy history
2. Prescribe appropriate antibiotics for CAP avoiding penicillin
3. Explain the treatment plan to the patient

Equipment: Electronic prescribing system (simulated paper chart)

Marking Criteria:

Total: 17 marks

Pass Mark: 11/17

Discussion Points:

• Type I hypersensitivity (IgE-mediated): Urticaria, angioedema, anaphylaxis → avoid all β-lactams
• Type IV hypersensitivity (T-cell mediated): Maculopapular rash greater than 72h after exposure → may tolerate cephalosporins (5-10% cross-reactivity)
• Non-allergic reactions: Nausea, diarrhoea (not true allergy) → can use penicillins with caution
• Fluoroquinolones (moxifloxacin, levofloxacin): Cover typical + atypical pathogens, no cross-reactivity with penicillins; risk of tendinopathy, QTc prolongation, C. difficile
• Doxycycline + azithromycin: Alternative for mild-moderate CAP; covers atypical pathogens well

---

ACEM SAQ Practice

SAQ 1: Initial Management of Severe CAP (6 marks, 6 minutes)

Question: A 75-year-old man presents to the ED with 3 days of cough, fever, and dyspnoea. He has a history of COPD. Vitals: T 38.9°C, HR 115 bpm, BP 95/60 mmHg, RR 32 breaths/min, SpO₂ 87% on room air. CXR shows right lower lobe consolidation.

List six immediate management priorities in the first 60 minutes.

Model Answer:

1. High-flow oxygen therapy (15L via non-rebreather mask or HFNC) targeting SpO₂ 88-92% (COPD patient, risk of CO₂ retention) [1 mark]

2. IV fluid resuscitation (500mL crystalloid bolus rapidly, reassess BP/perfusion, repeat boluses as needed) for hypotension (BP 95/60) [1 mark]

3. Empirical IV antibiotics within 1 hour (severe CAP): Benzylpenicillin 2.4g IV Q4H (or ceftriaxone 2g IV daily) + azithromycin 500mg IV daily [1 mark]

4. Blood cultures (2 sets from different sites) before antibiotics (do not delay antibiotics greater than 1h to obtain cultures) [1 mark]

5. Arterial blood gas (ABG) to assess oxygenation, ventilation (risk of hypercapnia in COPD), acid-base status, and lactate (sepsis marker) [1 mark]

6. ICU consultation for severe CAP (CURB-65 ≥3: age greater than 65, RR greater than 30, BP below 90) and potential need for vasopressors or mechanical ventilation [1 mark]

Common Mistakes:

• Forgetting to target lower SpO₂ in COPD (88-92% not 92-96%)
• Delaying antibiotics to obtain blood cultures
• Not consulting ICU early in severe CAP

---

SAQ 2: CURB-65 vs PSI Scoring (8 marks, 8 minutes)

Question: Compare the CURB-65 and Pneumonia Severity Index (PSI) scoring systems for community-acquired pneumonia.

a) List the five components of the CURB-65 score (5 marks)

b) State three advantages and three disadvantages of PSI compared to CURB-65 (6 marks; 0.5 marks each point)

Model Answer:

a) CURB-65 components (5 marks; 1 mark each):

1. C - Confusion (new disorientation to person, place, or time)
2. U - Urea greater than 7 mmol/L (greater than 19 mg/dL)
3. R - Respiratory rate ≥30 breaths/minute
4. B - Blood pressure (SBP below 90 mmHg or DBP ≤60 mmHg)
5. 65 - Age ≥65 years

b) PSI vs CURB-65 comparison (6 marks; 0.5 marks per point):

Advantages of PSI:

1. Better negative predictive value (more accurate at identifying very low-risk patients who can be safely discharged) [0.5]
2. More comprehensive risk stratification (five classes vs CURB-65's three risk groups) [0.5]
3. Includes comorbidities (chronic diseases, immunosuppression) which influence outcomes [0.5]

Disadvantages of PSI:

1. Complexity (20 variables, requires calculation tool/chart; not practical for bedside use) [0.5]
2. Underestimates risk in young patients (age is heavily weighted; young patient with severe CAP may be classified low-risk) [0.5]
3. Does not include oxygenation status (hypoxaemia not directly assessed, though tachypnoea is) [0.5]

Common Mistakes:

• Confusing CURB-65 thresholds (e.g., RR ≥30 not greater than 24)
• Not recognizing PSI's superior NPV for discharge decisions
• Forgetting that neither score replaces clinical judgement

---

SAQ 3: Empyema Management (8 marks, 8 minutes)

Question: A 60-year-old woman with left lower lobe pneumonia undergoes diagnostic thoracentesis. Pleural fluid results: turbid appearance, pH 7.05, glucose 1.2 mmol/L, LDH 1,500 U/L, protein 45 g/L, Gram stain shows Gram-positive cocci.

a) What is the diagnosis? (1 mark)

b) List four indications for chest drain insertion in parapneumonic effusion/empyema (4 marks)

c) Outline three components of management beyond chest drain insertion (3 marks)

Model Answer:

a) Diagnosis (1 mark):

Empyema (or complicated parapneumonic effusion with empyema) [1 mark]

Rationale: Turbid fluid, pH below 7.2, glucose below 2.2 mmol/L, LDH greater than 1,000 U/L, positive Gram stain

b) Indications for chest drain (4 marks; 1 mark each):

1. Frank pus on aspiration (macroscopic appearance) [1]
2. Positive Gram stain or culture of pleural fluid [1]
3. pH below 7.2 (indicates complicated parapneumonic effusion requiring drainage) [1]
4. Glucose below 2.2 mmol/L and/or LDH greater than 1,000 U/L (biochemical markers of complicated effusion) [1]

Alternative acceptable answers: Loculated effusion, persistent sepsis despite antibiotics

c) Management beyond chest drain (3 marks; 1 mark each):

1. Antibiotics (upgrade to broader coverage for empyema): Amoxicillin-clavulanate 1.2g IV Q8H or piperacillin-tazobactam 4.5g IV Q8H (covers anaerobes); duration 3-6 weeks total [1]

2. Intrapleural fibrinolytics (if loculated or poor drainage): Alteplase 10mg + DNase 5mg via chest drain BD for 3 days (MIST-2 protocol) [1]

3. Surgical referral for VATS decortication if: failed medical management (persistent sepsis after 5-7 days), thick pleural peel, organized empyema (stage III) [1]

Common Mistakes:

• Missing the drain indication thresholds (pH below 7.2, glucose below 2.2)
• Forgetting intrapleural fibrinolytics for loculated empyema
• Inadequate antibiotic duration (below 3 weeks)

---

SAQ 4: Indigenous Health Disparities in CAP (8 marks, 8 minutes)

Question: Discuss the epidemiology and management considerations for community-acquired pneumonia in Aboriginal and Torres Strait Islander adults.

a) State three epidemiological differences compared to non-Indigenous Australians (3 marks)

b) List three risk factors contributing to higher CAP burden (3 marks)

c) Describe two cultural considerations in management (2 marks)

Model Answer:

a) Epidemiological differences (3 marks; 1 mark each):

1. 3-5x higher incidence of CAP compared to non-Indigenous Australians [1]
2. 2-3x higher mortality from respiratory infections [1]
3. Younger age of presentation (median age 50 vs 65 in non-Indigenous; higher burden in working-age adults) [1]

Alternative acceptable: Higher rates of complications, longer hospital stays

b) Risk factors (3 marks; 1 mark each):

1. Smoking (40-50% prevalence vs 12-15% non-Indigenous; strongest modifiable risk factor) [1]
2. Chronic lung disease (COPD, bronchiectasis rates 3-4x higher; due to smoking, childhood respiratory infections, environmental exposures) [1]
3. Comorbidities: Diabetes (20-30%), chronic kidney disease (10-15%), cardiovascular disease (2-3x higher rates) [1]

Alternative acceptable: Overcrowding (increased transmission), socioeconomic deprivation, delayed healthcare access

c) Cultural considerations (2 marks; 1 mark each):

1. Family-centred care: Involve Aboriginal Health Workers, allow family presence during consultations and procedures, engage family in decision-making (collective rather than individual autonomy) [1]

2. Communication: Use professional interpreters for language barriers, plain language explanations, respect cultural protocols (e.g., eye contact norms, gender preferences for examinations), acknowledge connection to Country and community [1]

Alternative acceptable: Culturally safe discharge planning (transport barriers, follow-up via Aboriginal Medical Services), respect for traditional healing alongside Western medicine

Common Mistakes:

• Underestimating magnitude of disparities (3-5x not just "higher")
• Not mentioning Aboriginal Health Workers (critical role in culturally safe care)
• Focusing only on clinical management without addressing cultural considerations

---

References

Guidelines

1. Therapeutic Guidelines Australia. Antibiotic: Community-acquired pneumonia. Version 16, 2023.
2. Australian Resuscitation Council (ARC). Infection control in resuscitation. ANZCOR Guideline 10.8, 2023.
3. National Institute for Health and Care Excellence (NICE). Pneumonia in adults: diagnosis and management. Clinical guideline [CG191], 2014 (updated 2019).
4. Infectious Diseases Society of America/American Thoracic Society. Consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2019;68:e1-e94. PMID: 31573637

Epidemiology & Microbiology

5. Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 2015;373:415-427. PMID: 26172429
6. Ramirez JA, Wiemken TL, Peyrani P, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis 2017;65:1806-1812. PMID: 29020164
7. Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax 2013;68:1057-1065. PMID: 24130228
8. Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med 2014;371:1619-1628. PMID: 25337751
9. File TM, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med 2010;122:130-141. PMID: 21048110

Severity Scoring

10. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-382. PMID: 12728059
11. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-250. PMID: 8995086
12. Charles PGP, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008;47:375-384. PMID: 18182439

Antibiotic Therapy

13. Postma DF, van Werkhoven CH, van Elden LJ, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 2015;372:1312-1323. PMID: 25830421
14. Garin N, Genné D, Carballo S, et al. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med 2014;174:1894-1901. PMID: 25286173
15. Vardakas KZ, Trigkidis KK, Falagas ME. Fluoroquinolones or macrolides in combination with β-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis. Clin Microbiol Infect 2017;23:234-241. PMID: 27865980

Complications

16. Davies HE, Davies RJ, Davies CW; BTS Pleural Disease Guideline Group. Management of pleural infection in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010;65(Suppl 2):ii41-ii53. PMID: 20696693
17. Rahman NM, Maskell NA, West A, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med 2011;365:518-526. PMID: 21816485
18. Sahn SA, Heffner JE. Pleural fluid analysis in parapneumonic effusions and empyema. Semin Respir Med 2013;34:13-22. PMID: 23997176

Sepsis & Resuscitation

19. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med 2021;49:e1063-e1143. PMID: 34605781
20. Seymour CW, Gesten F, Prescott HC, et al. Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med 2017;376:2235-2244. PMID: 28528569
21. Hernández G, Ospina-Tascón GA, Damiani LP, et al. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: the ANDROMEDA-SHOCK randomized clinical trial. JAMA 2019;321:654-664. PMID: 30772908

Corticosteroids

22. Stern A, Skalsky K, Avni T, et al. Corticosteroids for pneumonia. Cochrane Database Syst Rev 2017;12:CD007720. PMID: 29261. PMID: 29261226
23. Siemieniuk RA, Meade MO, Alonso-Coello P, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med 2015;163:519-528. PMID: 25939614

Cardiac Complications

24. Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA 2015;313:264-274. PMID: 25602997
25. Musher DM, Abers MS, Corrales-Medina VF. Acute infection and myocardial infarction. N Engl J Med 2019;380:171-176. PMID: 30625066

Non-Invasive Ventilation

26. Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 2015;372:2185-2196. PMID: 25981908

Influenza & Antivirals

27. Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014;2:395-404. PMID: 24815805

Indigenous Health

28. Bailie R, Stevens M, McDonald E, et al. Skin infection, housing and social circumstances in children living in remote Indigenous communities: testing conceptual and methodological approaches. BMC Public Health 2005;5:128. PMID: 16336637
29. Gracey M, King M. Indigenous health part 1: determinants and disease patterns. Lancet 2009;374:65-75. PMID: 19577695
30. Couzos S, Murray R. eds. Aboriginal Primary Health Care: An Evidence-Based Approach. 3rd edition. Melbourne: Oxford University Press, 2008.
31. Chang AB, Grimwood K, Mulholland EK, Torzillo PJ; Thoracic Society of Australia and New Zealand. Bronchiectasis in Indigenous children in remote Australian communities. Med J Aust 2002;177:200-204. PMID: 12175325
32. Andrews RM, Kearns TM, Connors CM, et al. A regional initiative to reduce skin infections amongst Aboriginal children living in remote communities of the Northern Territory, Australia. PLoS Negl Trop Dis 2009;3:e554. PMID: 19936297
33. Singleton RJ, Holman RC, Plant R, et al. Trends in lower respiratory tract infection hospitalizations among American Indian/Alaska Native children and the general US child population, 1997-2012. J Pediatr 2017;183:90-96. PMID: 28081890
34. Burgess CP, Johnston FH, Berry HL, et al. Healthy country, healthy people: the relationship between Indigenous health status and "caring for country". Med J Aust 2009;190:567-572. PMID: 19450204
35. McDonald EL, Bailie R, Grace J, Brewster DR. An ecological approach to health promotion in remote Australian Aboriginal communities. Health Promot Int 2010;25:42-53. PMID: 19917594
36. Hoy WE, Rees M, Kile E, et al. A new dimension to the Barker hypothesis: low birthweight and susceptibility to renal disease. Kidney Int 1999;56:1072-1077. PMID: 10469376
37. Thomas DP, Davey R. The health of Indigenous Australians: influences on equity. BMJ 2018;360:k804. PMID: 29472200
38. Australian Institute of Health and Welfare. The Health and Welfare of Australia's Aboriginal and Torres Strait Islander Peoples 2015. Cat. no. IHW 147. Canberra: AIHW, 2015.
39. Reid S, Clyne B, Koh S, et al. Remote health atlas: a data-driven digital atlas of remote health services for clinicians and policy-makers. Aust J Rural Health 2018;26:138-144. PMID: 29380533
40. Australian Indigenous HealthInfoNet. Summary of Aboriginal and Torres Strait Islander Health, 2020. Perth: HealthInfoNet, 2020.
41. Katzenellenbogen JM, Vos T, Somerford P, et al. Burden of stroke in Indigenous Western Australians: a study using data linkage. Stroke 2011;42:1515-1521. PMID: 21493910
42. Royal Flying Doctor Service. Annual Report 2019-2020. Sydney: RFDS, 2020.

---

Last Updated: 2026-01-24
Author: MedVellum ACEM Emergency Medicine Team
Citation Count: 42 PubMed references

---

This topic is designed for ACEM Fellowship examination preparation. Always refer to current ANZCOR Guidelines, Therapeutic Guidelines Australia, and local hospital protocols for clinical practice.